Regeneron Pharmaceuticals Inc. (REGN) carries a Roarable Rating of C+ (Hold) with 67/100 RQD Confidence. The underlying business is intact, so current owners don’t need to panic-sell—but mixed big-money flow or rich pricing means new buyers can afford to wait for either a pullback or a B-or-higher upgrade.
Regeneron Pharmaceuticals Inc. (REGN) advanced +0.68% to $818.77 as options desks priced 54% call premium vs. 46% put protection around the $802 max-pain magnet. Solid 41% profit margin (9% return on capital), mixed timing at 19x P/E—hold if owned, no rush to chase.
Regeneron Pharmaceuticals has rallied hard in recent years, and with the stock around US$928.61 after a sharp climb, the real question is whether that share price still lines up with the earnings power investors are payi
Regeneron Pharmaceuticals reported third quarter 2026 revenue of US$5,115.8 million and net income of US$1,948.7 million, alongside a quarterly dividend of US$0.94 per share and ongoing share repurchases under its April
An early-stage liver disease therapy cut fat by 70% in just 12 weeks, signaling the genetics engine's potential to fuel growth beyond current blockbusters.
Regeneron rallied to a two-year high as Dupixent drives strong Q3 earnings. But is there any further upside left in REGN shares? Let’s find out!
Regeneron Pharmaceuticals (REGN) moved sharply after reporting third quarter 2026 results, with revenue of US$5.12b and net income of US$1.95b, along with stronger non GAAP earnings and record contributions from Dupixent
Shares of biotech company Regeneron (NASDAQ:REGN) jumped 11.5% in the afternoon session after the company reported a 36% increase in third-quarter 2026 revenue to $5.1 billion, alongside a 70% rise in non-GAAP diluted ea
Regeneron stock jumped to a two-year high Friday after its Sanofi-partnered inflammation giant, Dupixent, handily beat expectations.
US equity indexes ended lower Friday amid a sell-off in the technology sector after Intel's (INTC) Q
S&P 500 top percentage movers in today's US session, led by FDXF gainer and INTC decliner, with gainers and losers ranked by latest prices.
Regeneron's Q3 earnings and revenues beat estimates, fueled by strong Dupixent profits, Eylea HD growth and robust Libtayo demand. Stock up.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +1.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on REGN today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for REGN. Explore sector supply chains on /butterfly.
Why REGN Stock advanced +0.68% Today — RQD Quant Desk Flash. Solid 41% profit margin (9% return on capital), mixed timing at 19x P/E—hold if owned, no rush to chase.